| The Accelerating Medicines Partnership® program - Schizophrenia (AMP® SCZ) is introducing a new website to provide a centralized space for people to learn about the program and find the latest AMP SCZ news. The AMP SCZ program is a public-private partnership between the National Institutes of Health, the U.S. Food and Drug Administration, the European Medicines Agency, and multiple public and private organizations. The program, managed through the Foundation for the National Institutes of Health, aims to clarify the disease pathways and long-term outcomes of people who are at risk for schizophrenia and to identify new and better targets for early treatment. To achieve these aims, the program will establish an international research network focused on recruiting nearly 2,500 young people who have shown signs of early risk for schizophrenia from 42 study sites around the globe. The National Institute of Mental Health (NIMH) is currently supporting three research projects as part of the AMP SCZ program. As part of this innovative collaborative partnership, all AMP SCZ data and analyses will be available to the broad biomedical community through the NIMH Data Archive. The new AMP SCZ website provides helpful information for young people, family members, and clinicians who would like to learn about participating in an AMP SCZ study. The website also includes detailed information for scientists who want to know more about study design, data sharing, and more. | 
No comments:
Post a Comment